Aren´t there 1000 more likely options:
- Discussing changes in protocol (with FDA)
- Updating procedures, tracking, feedback in case of SAEs
- Reviewing and rediscussing the trials with the physicians and institutions involved
- New waivers signed from all participants
- Reviewing that started trials are still meaningful (dosing, money spent for trials vs reward, etc.)
etc
If Harvey is serious about shareholder value first, then his first priorities are
1) Iclusiq sales/pricing approvals with current indications/approvals in additional geographies
2) Start of ´113 pivotal trial
3a) If data is good: Iclusiq GIST pivotal trial (might not need to reopen ongoing trial since nearly fully enrolled)
3b) next molecule
All other halted trials are of lower importance than the actions listed above, IMO.
